Bigger and better: how Pfizer redefined erectile dysfunction.
Lexchin
Joel
J
School of Health Policy and Management, York University, Toronto, Ontario, Canada. jlexchin@yorku.ca
D000293:Adolescent; D000328:Adult; D000329:Advertising; D000367:Age Factors; D016527:Drug Costs; D004345:Drug Industry; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000523:psychology; D019317:Evidence-Based Medicine; D006801:Humans; D019458:Insurance Coverage; D008019:Life Style; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D015995:Prevalence; D011687:Purines; D040841:Resource Allocation; D012720:Severity of Illness Index; D000068677:Sildenafil Citrate; D012924:Social Conditions; D013450:Sulfones; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000191:economics / Q000627:therapeutic use*
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate